

Medigen Biotechnology Corp. (3176 MEDIGEN)

SEQ_NO	2	Date of announcement	2023/06/26	Time of announcement	17:43:03
Subject	Additional Independent Director elected at the Company's 2023 Annual Shareholder's Meeting				
Date of events	2023/06/26	To which item it meets	paragraph 6		
Statement	<p>1. Date of occurrence of the change: 2023/06/26</p> <p>2. Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): Independent director</p> <p>3. Title and name of the previous position holder: N/A</p> <p>4. Resume of the previous position holder: N/A</p> <p>5. Title and name of the new position holder: Independent director Lin, Sheue-Rong</p> <p>6. Resume of the new position holder: Commissioner of Department of Health, New Taipei City Government CEO of Liver Disease Prevention & Treatment Research Foundation</p> <p>7. Circumstances of change (Please enter "resignation", "dismissal", "term expired", "death" or "new appointment"): new appointment</p> <p>8. Reason for the change: Add one more independent director to the Board</p> <p>9. Number of shares held by the new position holder when elected: 0</p> <p>10. Original term (from _____ to _____): N/A</p> <p>11. Effective date of the new appointment: 2023/06/26</p> <p>12. Turnover rate of directors of the same term: 1/8</p> <p>13. Turnover rate of independent directors of the same term: 1/4</p> <p>14. Turnover rate of supervisors of the same term: N/A</p> <p>15. Change in one-third or more of directors (Please enter "Yes" or "No"): No</p> <p>16. Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): none</p>				